Vasopressin and vasopressin receptor antagonists in heart failure

Cardiology in Review

Volumn 17, Issue 1, 2009, Pages 10-15

  Oghlakian, Gerard ^a   Klapholz, Marc ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Aquaresis; Congestive heart failure; Receptors; Vasopressin; Vasopressin antagonists

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; ARGIPRESSIN; ARGIPRESSIN RECEPTOR; CONIVAPTAN; DESMOPRESSIN; DIURETIC AGENT; ELECTROLYTE; FUROSEMIDE; LIXIVAPTAN; MOZAVAPTAN; TERLIPRESSIN; TOLVAPTAN; WATER; ANTIDIURETIC AGENT; VASOPRESSIN RECEPTOR;

ACUTE HEART FAILURE; ANXIETY; BACKACHE; BLEEDING DISORDER; CLINICAL TRIAL; DIABETES INSIPIDUS; DIURESIS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ELECTROLYTE DISTURBANCE; ENDOCRINE DISEASE; ESOPHAGUS VARICES BLEEDING; HEART FAILURE; HEMATURIA; HUMAN; HYPERNATREMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MORTALITY; NONHUMAN; POLYURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM ACTIVATION; REVIEW; SIDE EFFECT; SURVIVAL; TACHYCARDIA; THIRST; VASOCONSTRICTION; WATER RETENTION; XEROSTOMIA; ANIMAL; DRUG ANTAGONISM; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTIDIURETIC AGENTS; ARGININE VASOPRESSIN; HEART FAILURE; HUMANS; RECEPTORS, VASOPRESSIN;

EID: 59849121934     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e318190e72c     Document Type: Review

References (86)

1. Sachs H. Biosynthesis and release of vasopressin. Am J Med. 1967;42:687- 700.
2. Turner RA, Pierce JG, Du Vigneaud V. The purification and the amino acid content of vasopressin preparations. J Biol Chem. 1951;191:21-28.
3. Davoll H, Turner RA, Pierce JG, et al. An investigation of the free amino groups on oxytocin and desulfurized oxytocin preparations. J Biol Chem. 1951;193:363-370.
4. Manning M, Sawyer W. Discovery, development, and some uses of vaso-pressin and oxytocin antagonists. J Lab Clin Med. 1989;114:617-632.
5. Frishman WH, Klapholz M, Acharya N, et al. Vasopressin and vasopressin-receptor antagonists in the treatment of cardiovascular disease. In: Frishman WH, Sonnenblick EH, Sica DA, eds. Cardiovascular Pharmacotherapeutics. 2nd ed. New York, NY: McGraw Hill. 2003:601-616.
6. DeKeyzer Y, Auzan C, Lenne F, et al. Cloning and characterization of the human V3 pituitary vasopressin receptors. FEBS Lett. 1994;345:215-220.
7. Fahrenholz F, Jurzak M, Gerstberger R, et al. Renal and central vasopressin receptors: immunocytochemical localization. Ann NY Acad Sci. 1993;689: 194-206.
8. McKinley MJ, Congiu M, Denton DA, et al. The anterior wall of the third cerebral ventricle and homeostatic responses to dehydration. J Physiol-Paris. 1984;79:421-427.
9. Stehle J, Reuss S, Riemann R, et al. The role of arginine vasopressin for pineal melatonin synthesis in the rat: involvement of vasopressinergic recep-tors. Neurosci Lett. 1991;123:131-134.
10. Kasting NW. Criteria for establishment of a physiological role for brain peptides. A case in point: the role of vasopressin in thermoregulation during fever and antipyresis. Brain Res Rev. 1989;14:143-153.
11. Meisenberg G, Simmons WH. Hypothermia induced by centrally adminis- tered vasopressin in rats: a structure-activity study. Neuropharmacol. 1984; 23:1195-1200.
12. Whitnall MH. Stress selectively activates the vasopressin-containing subset of corticotropin-releasing hormone neurons. Neuroendocrin. 1989;50:702-707.
13. Gibbs DM. Vasopressin and oxytocin: hypothalamic modulators of the stress response: a review. Psychoneuroendocrinol. 1986;11:131-139.
14. Diamant M, DeWied D. Differential effects of centrally injected AVP on heart rate, core temperature, and behavior in rats. Am J Physiol. 1993;264: R51-R61.
15. Zimmerman EA, Ma L-Y, Nilaver G. Anatomical basis of thirst and vasopressin secretion. Kidney Int Suppl. 1987;21:S14-S19.
16. Abramow M, Beauwens R, Cogan E. Cellular events in ADH action. Kidney Int Suppl. 1987;21:S56-S66.
17. Andrews CE, Brenner BM. Relative contributions of arginine vasopressin and angiotensin II to maintenance of systemic arterial pressure in the anaesthetized water deprived rat. Circ Res. 1981;48:254-258.
18. Woods RL, Johnston CI. Contribution of vasopressin to the maintenance of blood pressure during dehydration. Am J Physiol. 1983;245(5 Pt 1):F615-F621.
19. McNeill JR, Stark RD, Greenway CV. Intestinal vasoconstriction after hemorrhage: roles of vasopressin and angiotensin. Am J Physiol. 1970;219:1342-1347.
20. Bichet D, Szatalowicz V, Chaimovitz C, et al. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med. 1982;96:413-417.
21. Tsuboi Y, Ishikawa S, Fujisawa G, et al. Therapeutic efficacy of the non-peptide AVP antagonist OPC 31260 in cirrhotic rats. Kidney Int. 1994;46: 237-244.
22. Antoni FA. Receptors mediating the CRH effects of vasopressin and oxytocin. Ann NY Acad Sci. 1987;512:195-204.
23. Baertschi AJ, Friedli M. A novel type of vasopressin receptor on anterior pituitary corticotrophs. Endocrinol. 1985;116:499-502.
24. Chase LR, Aurbach GD. Renal adenyl cyclase: anatomically separate sites for parathyroid hormone and vasopressin. Science. 1968;159:545-547.
25. Kirk CJ, Verrinder TR, Hems DA. Rapid stimulation by vasopressin and adrenaline of inorganic phosphate incorporation into phosphatidyl inositol in isolated hepatocytes. FEBS Lett. 1977;83:267-271.
26. Butlen D, Guillon G, Rajerison RM, et al. Structural requirements for activation of vasopressin-sensitive adenylate cyclase, hormone binding, and anti-diuretic actions: effects of highly potent analogues and competitive inhibitors. Molec Pharmacol. 1978;14:1006-1017.
27. Michell RK, Kirk CJ, Billah MM. Hormonal stimulation of phosphatidylino-sitol breakdown with particular reference to the hepatic effects of vasopressin. Biochem Soc Trans. 1979;7:861-865.
28. Aiyar N, Nambi P, Stassen FL, et al. Vascular vasopressin receptors mediate phosphatidylinositol turnover and calcium efflux in an established smooth muscle cell line. Life Sci. 1986;39:37-45.
29. Antoni FA. Novel ligand specificity of pituitary vasopressin receptors in the rat. Neuroendocrin. 1984;39:186-188.
30. 1 vasopressin receptors. J Recept Res. 1989;9: 27-41.
31. 2 receptors in rat kidney. Endocrinol. 1988;122:1328-1336.
32. Nambi P, Whitman M, Gessner G, et al. Vasopressin-mediated inhibition of atrial natriuretic factor-stimulated cGMP accumulation in an established smooth muscle cell line. Proc Natl Acad Sci USA. 1986;83:8492-8495.
33. 1a type. Am J Physiol. 1987;253:F41-F49.
34. Nabika T, Velletri PA, Lovenberg W, et al. Increase in cytosolic calcium and phosphoinositide metabolism induced by angiotensin II and [arg]vasopressin in vascular smooth muscle cell. J Biol Chem. 1985;260:4661-4670.
35. Tahara A, Tomura Y, Wada K, et al. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced hyperplasia and hypertrophy of cultured vascular smooth-muscle cells. J Cardiovasc Pharmacol. 1997;30 759-766.
36. Tahara A, Saito M, Tsukada J, et al. Vasopressin increases vascular endothelial growth factor secretion from human vascular smooth muscle cells. Eur J Pharmacol. 1999;26:89-94.
37. 2-agonism in dogs. Am J Physiol. 1989;256:H1621-H1626.
38. 1-vascular vasopressin receptors. Reg Peptides. 1992;38:1-11.
39. Harris HW Jr, Strange K, Zeidel M. Current understanding of the cellular biology and molecular structure of antidiuretic hormone-stimulated water transport pathway. J Clin Invest. 1991;88:1-8.
40. Maggi M, Baldi E, Genazzani AD, et al. Vasopressin receptors in human seminal vesicles: identification, pharmacologic characterization, and comparison with the vasopressin receptors present in the human kidney. J Androl. 1989;10:393-400.
41. Kumar R. Endocytosis of the vasopressin receptor. Semin Nephrol. 1994;14: 357-367.
42. Dell'Era A, de Franchis R, Iannuzzi F. Acute variceal bleeding: pharmacological treatment and primary/secondary prophylaxis. Best Pract Res Clin Gastroenterol. 2008;22:279-294.
43. Undesser KP, Hasser EM, Haywood JR, et al. Interactions of vasopressin with the area postrema in arterial baroreflex function in conscious rabbits. Circ Res. 1985;56:410-417.
44. 1 receptors in the area postrema. Circ Res. 1990;67:265-271.
45. Suzuki S, Takeshita A, Imaizumi T, et al. Central nervous system mechanisms involved in inhibition of renal sympathetic nerve activity induced by arginine vasopressin. Circ Res. 1989;65:1390-1399.
46. Malpas SC, Coote JH. Role of vasopressin in sympathetic response to paraventricular nucleus stimulation in anesthetized rats. Am J Physiol. 1994; 266:R228-R236.
47. Wang YX, Crofton JT, Share L. Sex differences in the cardiovascular and renal actions of vasopressin in conscious rats. Am J Physiol. 1997;272(1 pt 2):R370-R376.
48. Eatman D, Stallone JN, Rutecki GW, et al. Sex differences in extracellular and intracellular calcium-mediated vascular reactivity to vasopressin in rat aorta. Eur J Pharmacol. 1998;20:207-216.
49. 2-induced vasodilation in dogs. Am J Physiol. 1994;26:H99-H106.
50. Leier CV, Dei Cas L, Metra M. Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. Am Heart J. 1994;128:254.
51. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuro-endocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724-1729.
52. Bakris G, Bursztyn M, Gavras I, et al. Role of vasopressin in essential hypertension: racial differences. J Hyperten. 1997;15:545-550.
53. Gavras H. Role of vasopressin in clinical hypertension and congestive cardiac failure: interaction with the sympathetic nervous system. Clin Chem. 1991; 37(10 Pt 2):1828-1830.
54. Rouleau JL, Packer M, Moye L, et al. Prognostic value of neurohormonal activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol. 1994;24:583-591.
55. Schrier RW. Water and sodium retention in edematous disorders: role of vasopressin and aldosterone. Am J Med. 2006;119(suppl 1):S47-S53.
56. Ribeiro A, Mulinari R, Gavras I, et al. Sequential elimination of pressor mechanisms in severe hypertension in humans. Hypertension. 1986;8(Suppl I):I-169.
57. Houck PC, Fiksen-Olsen MJ, Briton SL, et al. Role of angiotensin and vasopressin on blood pressure of ganglionic blocked dogs. Am J Physiol. 1983;244:H115-H120.
58. 2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur J Pharmacol. 1999;376:239-246.
59. 2-vasopressinergic receptors. Am J Physiol Heart Circ Physiol. 1988;255:H261-H265.
60. Gavras I, Hatinoglou S, Gavras H. The adrenergic system and the release and pressor action of vasopressin. Hypertension. 1986;8(Suppl II):163-167.
61. Nishida N, Ogura Y, Yamauchi T, et al. Treatment with cilazapril, angioten-sin converting enzyme inhibitor, changes the affinity of arginine vasopressin receptor in the kidney of the spontaneously hypertensive rat. Res Commun Chem Pathol Pharm. 1994;84:143-152.
62. Khokhar AM, Slater JDH, Ma J, et al. The cardiovascular effect of vasopres-sin in relation to its plasma concentration in man and its relevance to high blood pressure. Clin Endocrin. 1980;13:259-266.
63. Gavras H, Hatzinikolaou P, North WG, et al. Interaction of the sympathetic nervous system with vasopressin and renin in the maintenance of blood pressure. Hypertension. 1982;4:400-405.
64. Domanski M, Norman J, Pitt B, et al. Diuretic use, progressive heart failure and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll of Cardiol. 2003;42:705-708.
65. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290:2581-2587.
66. De Luca L, Klein L, Udelson JE, et al. Hyponatremia in patients with heart failure. Am J Cardiol. 2005;96:19L-23L.
67. Klein L, O'Connor CM, Leimberger JD, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation. 2005;111:2454-2460.
68. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol. 2005;46:1785.
69. 2-receptor antagonist: pharmacologic profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther . 1998;287:860-867.
70. 2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. Biochemical Pharmacol. 2008;75:1322-1330.
71. 2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther. 2000;292:288-294.
72. 2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003;107:2690-2696.
73. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963-1971.
74. Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297:1332.
75. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297:1319.
76. Udelson JE, Orlandi C, Ouyang J, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: the ECLIPSE international, multi-center, randomized, placebo-controlled trial. Heart Failure Society of America 2006 Scientific Meeting; September 19, 2007; Washington, DC. Recent and Late-Breaking Trials session.
77. 2 -receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099-2112.
78. Kruszynski M, Lammeck B, Manning M, et al. [1(ß-mercapto-ß- cyclopentamethyl-eneproprionic acid)2-(O-methyl)tyrosine] argin vasopressin and [1-(ß-mercapto-ß, ß-cyclopenta-methyleneproprionic acid)] argin vasopressin, two highly potent antagonists of the vasopressor response to arginine-vasopressin J Med Chem. 1980;23:364-368.
79. Lee CR, Watkins M, Patteron JH, et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J. 2003;146:9-18.
80. 5Tyr/Et/VAVP on the antidiuretic action of exogenous and endogenous vasopressin. Acta Endocrinol. 1984;106:52-55.
81. 2 receptor antagonist, in dogs. Eur J Pharmacol. 1997;321:225-230.
82. 1 receptor antagonist. Science. 1991;252:572-574.
83. 1 antagonist. Clin Exp Pharmacol Physiol. 1993;20:388-391.
84. 2 vasopressin receptor antagonist in normal subjects. Eur J Clin Pharmacol. 1999;55:633-637.
85. 2 vasopressin receptor antagonist in patients with advanced heart failure. Circulation. 2001;104:2417-2423.
86. 2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol. 2006;47:1615-1621.